What researches reveal about coronavirus so far

Three molecules that were elevated in severely ill patients - called LIGHT, Oncostatin-M and EN-RAGE - are linked with lung inflammation but have not previously been seen in COVID-19 patients, the researchers reported on Tuesday in the journal Science

A person crosses an empty Grand Ave in downtown during the outbreak of the coronavirus disease (COVID-19), in Los Angeles, California, US, on 13 August 2020Reuters

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Neuromuscular disease may be triggered by COVID-19

Researchers have added the muscle-weakening disease myasthenia gravis to the list of neurological problems linked to severe COVID-19.

Tremors, seizures, impaired consciousness and other nervous system issues already have been tied to severe COVID-19. In some instances, the virus appears to trick the body into attacking the brain by triggering the immune system to produce so-called autoantibodies, which mistakenly target a person's own tissues or organs.

In myasthenia gravis, autoantibodies attack nerve connections to muscles, and skeletal muscles involving breathing and moving parts of the body become weak after activity.

On Monday in the journal Annals of Internal Medicine, doctors described three patients without previous neurological or autoimmune disorders whose symptoms of myasthenia gravis began within a week after fevers related to COVID-19 started.

Severely ill patients also had bacterial debris, such as bacterial DNA and cell-wall materials, in their blood. The more debris, the sicker the patient, and the more inflammatory substances circulating in the blood

The time from the coronavirus infection to the beginning of myasthenia gravis symptoms “is consistent with the time from infection to symptoms in other neurologic disorders triggered by infections,” the researchers said.

They added that the findings add to “the growing evidence of other neurologic disorders with presumed autoimmune mechanisms after COVID-19 onset.”

Vaping by young people linked to higher COVID-19 risk

Vaping appears to be tied to markedly increased risks for getting COVID-19 among US teens and young adults.

Researchers analysed nationally representative survey data collected in May from 4,351 participants ages 13-24 years in a study published on Tuesday in the Journal of Adolescent Health.

Those who used both cigarettes and e-cigarettes in the previous 30 days were 4.7 times more likely to report having experienced COVID-19 symptoms compared with those who never smoked or vaped.

Among participants who tested for COVID-19, those who used just e-cigarettes were five times more likely to report a positive test.

Those who had ever used both e-cigarettes and cigarettes were seven times more likely to be diagnosed with COVID-19.

David Christiani of Harvard T.H. Chan School of Public Health, who was not involved in the research, told Reuters there are many reasons why people who vape would be at increased risk of getting COVID-19.

Studies have shown that “vaping liquids impair local immunity in the nose and the rest of the respiratory tract. Once those defenses are impaired, it's going to make people more viable to infection,” Christiani said.

Also, the study authors noted, vaping involves repeated touching of the mouth and face, which is associated with the spread of the virus.

Face masks could someday help diagnose illness

Some face masks are effective at limiting the spread of COVID-19, some are not - and some, researchers said, might eventually help diagnose illnesses unrelated to the coronavirus.

Researchers reported in the journal Science Advances that N95 masks are most effective, as long as they do not have a valve that lets the wearer's exhaled breath escape. Next most effective are surgical masks, followed by multiple-layer cotton masks. Bandanas only minimally curb the escape of exhaled droplets.

Fleece fabrics worn around the neck and pulled over the face “seemed to disperse the largest droplets into a multitude of smaller droplets” that remain airborne longer, so they “might be counterproductive,” the researchers said.

A separate report in the journal Analytical Chemistry explains that while molecules in exhaled breath can reveal disease, collecting enough molecules to diagnose a problem requires breathing into tubes or bags. But a specific kind of fiber insert placed inside a mask can collect enough molecules while wearers go about their usual activities.

After volunteers wore the masks with the inserts, examining the fiber insert using mass spectrometry let researchers see even trace amounts of exhaled particles.

Certain immune responses may contribute to severe COVID-19

Researchers who compared innate immune responses - the body's first line of defense - in patients with coronavirus infections and in healthy people found multiple differences that could shed light on COVID-19 and why some cases become so severe.

There were differences, for example, in the amounts and functioning of various types of cells in blood, in gene activity in cells isolated from blood, and in levels of inflammatory molecules.

In particular, three molecules that were elevated in severely ill patients - called LIGHT, Oncostatin-M and EN-RAGE - are linked with lung inflammation but have not previously been seen in COVID-19 patients, the researchers reported on Tuesday in the journal Science.

Severely ill patients also had bacterial debris, such as bacterial DNA and cell-wall materials, in their blood. The more debris, the sicker the patient, and the more inflammatory substances circulating in the blood.

But surprisingly, “although there were enhanced levels of inflammatory molecules in plasma, the blood cells themselves were in a state of functional sluggishness, and failed to respond efficiently to stimulation,” senior author Bali Pulendran of Stanford University told Reuters.

Overall, Pulendran said, “the study yields mechanistic insights and potential therapeutic targets for COVID-19.”